Arthritis, Rheumatoid
Conditions
Brief summary
The aim of this study is to evaluate the effectiveness and safety of Modified Zhiwang Decoction in combination with methotrexate for the treatment of early RA patients and a parallel-group, single-center randomized controlled clinical study was designed.
Detailed description
Rheumatoid Arthritis(RA) is a progressive inflammatory autoimmune disease characterized by chronic systemic inflammation, which can cause swelling, stiffening and articular cartilage and bone destruction. Early diagnosis and treatment in RA can improve outcomes and slow progression of joint damage. Modified Zhiwang Decoction(MZWD) has great curative effects for treating RA. However, few randomized clinical trials(RCTs) have evaluated the effectiveness of MZWD for the treatment of early RA. Therefore, a parallel-group randomized controlled trial was designed to evaluate the efficacy and safety of MZWD combined with methotrexate on early RA.
Interventions
DRUGModified Zhiwang Decoction Combined with methotrexate
Modified Zhiwang Decoction 100 ml (twice, per day) and methotrexate (7.5-15mg, once a week) for 12 weeks.
DRUGMethotrexate
Methotrexate(7.5-15mg, once a week) for 12 weeks.
Sponsors
Beijing University of Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged 16-70 years old; * Patients who meet the diagnostic criteria of 2010 ACR/EULAR . * Patients who meet the diagnostic criteria of cold pattern. * Disease activity score(DAS28) ≤5.2.
Exclusion criteria
* Patients accompanied with other rheumatic diseases or severe pain due to other medical conditions, such as diabetic pain or post-herpetic neuralgia; * Patients with joint dysfunction and the X-ray score of wrists is grade IV; * Patients accompanied with mental and psychological disorders such as cognitive impairment, depression, anxiety, physical dysfunction, cerebral infarction, cerebral hemorrhage, epilepsy, TIA, myelitis, demyelinating disease and other central nervous system diseases. * Patients accompanied with organ injury or malignant tumors, disorders of the cardiovascular system, liver(ALT/AST\>3 times higher than the upper limit of normal), kidneys(Ccr\<60ml/min), brain, or hematopoietic system. * Pregnant and lactating women. * Patients are participation in any other clinical trials. * Patients who are allergic to the drugs used in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DAS28 based on erythrocyte sedimentation rate scores | 12 weeks | DAS28 is widely accepted to evaluate RA disease activity and consists of number of tender joints out of 28, number of swollen joints out of 28, ESR and the patient's global assessment of disease activity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fatigue scale-14 | 12 weeks | The fatigue scale-14 is a standardized questionnaire regarding physical and mental fatigue. The higher the score, the greater the fatigue. |
| Visual analogue scale pain scores | 12 weeks | Visual analogue scale pain score is utilized to quantify the pain level that ranges from 0 to 10. A VAS score of 0 means no pain and a score of 10 means unbear-able pain. |
| Traditional chinese medicine symptom scores | 12 weeks | Traditional chinese medicine symptom score is calculated based on the percentage of symptom score reduction(PSSR) and the formula is as follows: PSSR=((symptom score before treatment-symptom score after treatemt)/(symptom score before treatment))×100% |
| Erythrocyte sedimentation rate | 12 weeks | — |
| C-reactive protein | 12 weeks | — |
Countries
China
Contacts
Primary ContactLiu-bo Zhang
Outcome results
None listed